Profusa to acquire PanOmics platform in $30M strategic pivot
Profusa (NASDAQ:PFSA) has entered into a non-binding letter of intent to acquire the PanOmics multi-omics diagnostics platform from BioInsights, a move that shifts the commercial-stage digital health company into the high-growth molecular diagnostics market.

-640x360.webp&w=3840&q=75)








